Drugs / SSS55
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07058779 | Aug 2025 → Dec 2026 expected | — | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSS55 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07058779 ↗ |
| Known as | SSS55 injection | “This study was a single-dose, randomized, double-blind, placebo-controlled study of SSS55 injection to evaluate the safety, tolerability, PK characteristics, immunogenicity and...” NCT07058779 ↗ |